A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies.

Trial Profile

A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Nesvacumab (Primary)
  • Indications Adrenocortical carcinoma; Liver cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 12 Oct 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 15 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Mar 2015 Planned End Date changed from 1 Jul 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top